Diaceutics (DXRX) Competitors

GBX 169.20 -2.80 (-1.63%)

As of 06:29 AM Eastern

DXRX vs. ABDX, GDR, YGEN, GENI, and AGL

Should you buy Diaceutics stock or one of its competitors? MarketBeat compares Diaceutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Diaceutics include Abingdon Health (ABDX), genedrive (GDR), Yourgene Health (YGEN), GENinCode (GENI), and ANGLE (AGL). These companies are all part of the "diagnostics & research" industry.

How does Diaceutics compare to Abingdon Health?

Abingdon Health (LON:ABDX) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Abingdon Health has higher earnings, but lower revenue than Diaceutics. Diaceutics is trading at a lower price-to-earnings ratio than Abingdon Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abingdon Health	£9.57M	2.89	-£796.37K	-£0.81	N/A
Diaceutics	£34.40M	4.16	-£2.84M	-£1.80	N/A

Abingdon Health has a beta of 0.117, meaning that its share price is 88% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

Diaceutics has a consensus price target of GBX 193.33, suggesting a potential upside of 14.26%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts clearly believe Diaceutics is more favorable than Abingdon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abingdon Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Abingdon Health had 1 more articles in the media than Diaceutics. MarketBeat recorded 1 mentions for Abingdon Health and 0 mentions for Diaceutics. Abingdon Health's average media sentiment score of 0.72 beat Diaceutics' score of 0.00 indicating that Abingdon Health is being referred to more favorably in the media.

Company	Overall Sentiment
Abingdon Health	Positive
Diaceutics	Neutral

3.7% of Abingdon Health shares are held by institutional investors. Comparatively, 32.7% of Diaceutics shares are held by institutional investors. 8.0% of Abingdon Health shares are held by company insiders. Comparatively, 26.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Diaceutics has a net margin of -4.42% compared to Abingdon Health's net margin of -33.88%. Diaceutics' return on equity of -3.94% beat Abingdon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abingdon Health	-33.88%	-55.91%	-17.93%
Diaceutics	-4.42%	-3.94%	-6.06%

Summary

Diaceutics beats Abingdon Health on 11 of the 16 factors compared between the two stocks.

How does Diaceutics compare to genedrive?

genedrive (LON:GDR) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

genedrive has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Diaceutics has higher revenue and earnings than genedrive. Diaceutics is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
genedrive	£929K	18.54	-£21.22M	-£0.79	N/A
Diaceutics	£34.40M	4.16	-£2.84M	-£1.80	N/A

In the previous week, genedrive's average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.

Company	Overall Sentiment
genedrive	Neutral
Diaceutics	Neutral

Diaceutics has a consensus price target of GBX 193.33, suggesting a potential upside of 14.26%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than genedrive.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
genedrive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Diaceutics has a net margin of -4.42% compared to genedrive's net margin of -500.75%. Diaceutics' return on equity of -3.94% beat genedrive's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
genedrive	-500.75%	-1,044.57%	-74.09%
Diaceutics	-4.42%	-3.94%	-6.06%

0.1% of genedrive shares are held by institutional investors. Comparatively, 32.7% of Diaceutics shares are held by institutional investors. 4.9% of genedrive shares are held by company insiders. Comparatively, 26.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Diaceutics beats genedrive on 11 of the 14 factors compared between the two stocks.

How does Diaceutics compare to Yourgene Health?

Yourgene Health (LON:YGEN) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

23.3% of Yourgene Health shares are held by institutional investors. Comparatively, 32.7% of Diaceutics shares are held by institutional investors. 64.4% of Yourgene Health shares are held by company insiders. Comparatively, 26.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Yourgene Health has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

In the previous week, Yourgene Health's average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.

Company	Overall Sentiment
Yourgene Health	Neutral
Diaceutics	Neutral

Diaceutics has a consensus price target of GBX 193.33, suggesting a potential upside of 14.26%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than Yourgene Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yourgene Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Diaceutics has a net margin of -4.42% compared to Yourgene Health's net margin of -27.55%. Diaceutics' return on equity of -3.94% beat Yourgene Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yourgene Health	-27.55%	-27.06%	-6.71%
Diaceutics	-4.42%	-3.94%	-6.06%

Diaceutics has higher revenue and earnings than Yourgene Health. Diaceutics is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yourgene Health	£29.67M	0.00	-£8.17M	-£0.01	N/A
Diaceutics	£34.40M	4.16	-£2.84M	-£1.80	N/A

Summary

Diaceutics beats Yourgene Health on 10 of the 13 factors compared between the two stocks.

How does Diaceutics compare to GENinCode?

Diaceutics (LON:DXRX) and GENinCode (LON:GENI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Diaceutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, GENinCode has a beta of 0.608, suggesting that its stock price is 39% less volatile than the broader market.

In the previous week, Diaceutics' average media sentiment score of 0.00 equaled GENinCode'saverage media sentiment score.

Company	Overall Sentiment
Diaceutics	Neutral
GENinCode	Neutral

32.7% of Diaceutics shares are owned by institutional investors. Comparatively, 4.8% of GENinCode shares are owned by institutional investors. 26.3% of Diaceutics shares are owned by insiders. Comparatively, 8.6% of GENinCode shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Diaceutics presently has a consensus price target of GBX 193.33, suggesting a potential upside of 14.26%. Given Diaceutics' stronger consensus rating and higher probable upside, research analysts plainly believe Diaceutics is more favorable than GENinCode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
GENinCode	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Diaceutics has a net margin of -4.42% compared to GENinCode's net margin of -170.49%. Diaceutics' return on equity of -3.94% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	-4.42%	-3.94%	-6.06%
GENinCode	-170.49%	-262.16%	-63.99%

Diaceutics has higher revenue and earnings than GENinCode. Diaceutics is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£34.40M	4.16	-£2.84M	-£1.80	N/A
GENinCode	£2.91M	2.66	-£6.10M	-£2.35	N/A

Summary

Diaceutics beats GENinCode on 13 of the 14 factors compared between the two stocks.

How does Diaceutics compare to ANGLE?

Diaceutics (LON:DXRX) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Diaceutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market.

In the previous week, ANGLE had 1 more articles in the media than Diaceutics. MarketBeat recorded 1 mentions for ANGLE and 0 mentions for Diaceutics. ANGLE's average media sentiment score of 0.67 beat Diaceutics' score of 0.00 indicating that ANGLE is being referred to more favorably in the news media.

Company	Overall Sentiment
Diaceutics	Neutral
ANGLE	Positive

32.7% of Diaceutics shares are owned by institutional investors. Comparatively, 17.5% of ANGLE shares are owned by institutional investors. 26.3% of Diaceutics shares are owned by company insiders. Comparatively, 2.7% of ANGLE shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Diaceutics presently has a consensus price target of GBX 193.33, suggesting a potential upside of 14.26%. Given Diaceutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Diaceutics is more favorable than ANGLE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
ANGLE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Diaceutics has a net margin of -4.42% compared to ANGLE's net margin of -732.40%. Diaceutics' return on equity of -3.94% beat ANGLE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	-4.42%	-3.94%	-6.06%
ANGLE	-732.40%	-89.82%	-29.89%

Diaceutics has higher revenue and earnings than ANGLE. Diaceutics is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£34.40M	4.16	-£2.84M	-£1.80	N/A
ANGLE	£2.62M	2.89	-£21.76M	-£4.80	N/A

Summary

Diaceutics beats ANGLE on 13 of the 16 factors compared between the two stocks.

Get Diaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXRX vs. The Competition

Export

Metric	Diaceutics	Diagnostics & Research Industry	Medical Sector	LON Exchange
Market Cap	£143.19M	£44.80M	£6.34B	£2.75B
Dividend Yield	N/A	3.62%	2.80%	6.07%
P/E Ratio	-94.00	0.84	20.66	365.85
Price / Sales	4.16	607.90	542.63	88,036.58
Price / Cash	3.12	11.42	43.26	27.89
Price / Book	3.69	3.42	9.93	7.68
Net Income	-£2.84M	£334.07B	£3.55B	£5.89B
7 Day Performance	-3.86%	-0.65%	1.70%	0.34%
1 Month Performance	3.17%	2.59%	0.49%	2.10%
1 Year Performance	29.26%	16.99%	39.41%	86.82%

Diaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXRX Diaceutics	N/A	GBX 169.20 -1.6%	GBX 193.33 +14.3%	+28.5%	£143.19M	£34.40M	N/A	151
ABDX Abingdon Health	N/A	GBX 12.21 -5.4%	N/A	+98.5%	£30.65M	£9.57M	N/A	84	Gap Down High Trading Volume
GDR genedrive	N/A	GBX 1.08 +17.0%	N/A	-23.8%	£17.28M	£929K	N/A	43	Gap Up High Trading Volume
YGEN Yourgene Health	N/A	N/A	N/A	N/A	£16.43M	£29.67M	N/A	253
GENI GENinCode	N/A	GBX 1.09 +3.6%	N/A	-29.3%	£7.89M	£2.91M	N/A	2,300	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:DXRX) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Diaceutics (DXRX) Competitors

DXRX vs. ABDX, GDR, YGEN, GENI, and AGL

How does Diaceutics compare to Abingdon Health?

Summary

How does Diaceutics compare to genedrive?

Summary

How does Diaceutics compare to Yourgene Health?

Summary

How does Diaceutics compare to GENinCode?

Summary

How does Diaceutics compare to ANGLE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXRX vs. The Competition

Diaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Diaceutics (DXRX) Competitors

DXRX vs. ABDX, GDR, YGEN, GENI, and AGL

How does Diaceutics compare to Abingdon Health?

Which has stronger valuation and earnings, ABDX or DXRX?

Which has more risk & volatility, ABDX or DXRX?

Do analysts rate ABDX or DXRX?

Does the media prefer ABDX or DXRX?

Do insiders and institutionals have more ownership in ABDX or DXRX?

Is ABDX or DXRX more profitable?

Summary

How does Diaceutics compare to genedrive?

Which has more volatility and risk, GDR or DXRX?

Which has preferable earnings and valuation, GDR or DXRX?

Does the media prefer GDR or DXRX?

Do analysts rate GDR or DXRX?

Is GDR or DXRX more profitable?

Do institutionals and insiders have more ownership in GDR or DXRX?

Summary

How does Diaceutics compare to Yourgene Health?

Do institutionals and insiders have more ownership in YGEN or DXRX?

Which has more volatility and risk, YGEN or DXRX?

Does the media prefer YGEN or DXRX?

Do analysts rate YGEN or DXRX?

Is YGEN or DXRX more profitable?

Which has preferable earnings and valuation, YGEN or DXRX?

Summary

How does Diaceutics compare to GENinCode?

Which has more volatility and risk, DXRX or GENI?

Does the media favor DXRX or GENI?

Do insiders & institutionals have more ownership in DXRX or GENI?

Do analysts prefer DXRX or GENI?

Is DXRX or GENI more profitable?

Which has higher earnings and valuation, DXRX or GENI?

Summary

How does Diaceutics compare to ANGLE?

Which has more risk and volatility, DXRX or AGL?

Does the media refer more to DXRX or AGL?

Do institutionals & insiders hold more shares of DXRX or AGL?

Do analysts prefer DXRX or AGL?

Is DXRX or AGL more profitable?

Which has stronger valuation & earnings, DXRX or AGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXRX vs. The Competition

Diaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools